Desmond Cabrera serves as Executive Director, Cell & Gene Therapies and brings over 15 years of experience in the CRO industry. In his current position, Desmond is the Global Therapeutic Operations Lead for Allucent’s Cell and Gene Portfolio in which he leads the strategy and team executing trials for sponsors who are developing CAG Therapies.
Desmond has gained extensive experience in the execution and management of clinical trials in all phases throughout his career and has worked at large CROs including ICON, IQVIA, Labcorp, and Parexel. He has led multinational teams and projects overseeing trials for oncology, pediatric, CNS and large-scale cardiovascular studies that involved 1,000+ sites and 25,000 patients. Desmond has overseen several early phase cell and gene therapy (CGT) projects involving feasibility and safety assessments, first-in-human studies, and dose escalation and expansion for oncology indications including breast and lung cancer, acute myeloid leukemia, and myelodysplastic syndrome.